To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter discusses the challenges in the scale-up of perfusion bioreactors from the few litres laboratory scale to the thousands of litres clinical and commercial scale. We consider comparative studies between laboratory- and large-scale reactor systems, including multiphase reactor models, computational fluidynamic tools as well as omics studies to support solid and reliable scale-up procedures. Specific scale-up issues – such as the scalability of the cell retention device, long-term operation, and batch definition in the case of process failure – are discussed. Finally, we evaluate the potential of single-use technologies and close the chapter with economic, financial, and environmental considerations in the context of future developments in biomanufacturing.
In this introductory chapter, we discuss mammalian cell culture for the production of therapeutic proteins in the broader context of biotechnology and, in particular, of the biopharmaceutical industry. We begin with a short retrospect on the history of cell cultures for bioproduct manufacturing and eventually introduce recombinant technology, in order to appreciate how the present standards were established. An overview of the current market on recombinant therapeutic proteins provides some important understanding of the industry challenges to come and the contribution that continuous manufacturing can provide. We then introduce the various bioreactor types that can be used in this area and indicate the challenges to be faced for their development, design, and operation. The objective here is to put all these aspects in the right perspective and address the reader to the chapters where each of them is specifically treated in the monography.
In this chapter, we give an overview of the challenges and objectives in operating mammalian cell perfusion cultures and provide guidelines for the design and set-up of lab-scale bioreactor systems. Next, the control structure needed to maintain long-term stable and viable cultures is illustrated, followed by a section on the media design. In the last section, we discuss steady-state operation, reactor, and process dynamics, including product quality considerations. Comparisons with current technologies, particularly with respect to product quality, are also discussed.
This chapter provides a general introduction for the application of mechanistic and statistical models in bioreactor process development and optimisation. We first introduce the equations governing the behaviour of batch and continuous stirred tank reactors (CSTR) for a given chemical system. After presenting the criteria to generalise these concepts to biological systems and bioprocesses, we discuss the implementation of mechanistic models for the simulation and control of the bioreactor performance with particular emphasis on product quality attributes, such as N-linked glycosylation. In addition, we describe the implementation of statistical and hybrid models and their application in process development and reactor optimisation. Lastly, we compare the use of the various modelling techniques for process monitoring and control.
The design and development of perfusion cultures require extensive experiental campaigns in order to identify the most convenient conditions in terms of a very large number of operating parameters. There is a need for high-throughput technologies that allow for the simultaneous operation and monitoring of several cultures at different process conditions. This requires suitable scale-down models, which allow the reliable prediction of the behaviour at larger scale. Within this chapter, we describe systems allowing the operation at the µL and mL scale and enabling early process development, such as clone and media screening, as well as the design of suitable process operating conditions at the larger scale. Managing such a high number of experiments is not possible without a proper level of automation, including suitable sensors for process monitoring.
The state-of-the-art strategies for perfusion process design, development, and optimisation are discussed. We first introduce the essential steps and boundaries for the development of a perfusion process. Next, we evaluate clone and media screening for perfusion processes and compare various alternative scale-down systems. Once the expression system is selected, we proceed with the design of the reactor operating conditions to maximise volumetric productivity and yield while reducing medium consumption. The fundamental issue of product quality attributes for biologics and biosimilars, and the impact of perfusion operating mode are also discussed. Finally, we introduce the main objectives in the scale-up of the developed process to clinical and commercial productions.
Master the design and operation of perfusion cell cultures with this authoritative reference. Discover the current state-of-the-art in the design and operation of continuous bioreactors, with emphasis on mammalian cell cultures for producing therapeutic proteins. Topics include the current market for recombinant therapeutic proteins, current industry challenges and the potential contribution of continuous manufacturing. Provides coverage of every step of process development and reactor operation, including small scale screening to lab-scale and scale-up to manufacturing scale. Illustrated through real-life case studies, this is a perfect resource for groups active in the cell culture field, as well as graduate students in areas such as chemical engineering, biotechnology, chemistry and biology, and to those in the pharmaceutical industry, particularly biopharma, biotechnology and food or agro industry.
This chapter provides a general introduction on biopharmaceutical processes. The first part presents a brief description of the single unit operations typically encountered during the manufacturing process, including cell culture, purification, viral inactivation, formulation. The second part addresses the potential benefits of continuous technologies in the biopharmaceutical industry both for the upstream and downstream parts of the process, focusing on perfusion bioreactors and continuous counter-current chromatographic processes, respectively. The chapter finishes with a discussion on process integration.
This chapter focusses on chromatographic processes for protein capture. The first part provides a detailed description of the mechanistic phenomena involved in protein capture, which can be regarded as a non-competitive binary system protein/impurity, where the protein of interest strongly interacts with the chromatographic medium. Several multi-column counter-current processes allowing the implementation of the sequence of operations necessary in protein capture (load, wash, recovery, regeneration) in a continuous manner are presented in the second part of the chapter. Two process design approaches for multi-column capture processes are provided: an empirical one, which allows to obtain a first guess of the operating conditions from breakthrough curves experiments, and a model-based one, which allows a more rigorous determination of the process variables. The model-based approach is used to compare the performance of multi-column and single-column processes.
This chapter deals with protein aggregation, which is a key issue in biopharmaceutical processes. Several experimental techniques to characterize the aggregate size and content are presented and fundamentals on the kinetic modelling of aggregation mechanisms are provided. The impact of operating conditions on the aggregation rate is reviewed and the steps critical for aggregate formation in biopharmaceutical processes are identified. Finally, methods aiming at reducing the aggregate content are proposed. These methods focus either on improving protein stability or on removing the formed aggregates. The former can be achieved by synthesizing aggregation-resistant proteins, tuning operating conditions, or designing processes with a shorter residence time (e.g. perfusion bioreactors or counter-current chromatography). The latter method is mainly achieved by filtration and chromatography. In particular, the simulated moving bed process is shown to be very advantageous for aggregate removal with size exclusion chromatography: it allows improving productivity, decreasing eluent consumption and increasing the outlet protein concentration as compared to single-column processes.
This chapter provides fundamentals on protein chromatography. Different chromatographic media are described in terms of the solute-surface interactions that can be exploited to achieve the desired separation. Then, mechanistic models are presented to describe the three key physical phenomena involved in protein chromatography, namely the thermodynamics of fluid-solid equilibrium, the hydrodynamics and the kinetics of mass transfer. Simple methods to estimate model parameters are introduced as well as short-cut methods to design chromatographic processes. Although the main goal of this chapter is to bring theoretical basics about the modelling of protein chromatography, it is complemented by numerous experimental results for illustrative and pedagogical purposes.